EQUIGARD - 450 HORSE ANTHELMINTIC Ավստրալիա - անգլերեն - APVMA (Australian Pesticides and Veterinary Medicines Authority)

equigard - 450 horse anthelmintic

vasco animal health products c/- virbac - not entered yet - parasiticides - horse | colt | donkey | endurance horse | filly | foal | gelding | high performance horses | horses at stud | mare | pacer | pol - not applicable (vet)

ELIGARD leuprorelin acetate 7.5mg modified release injection syringe Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

eligard leuprorelin acetate 7.5mg modified release injection syringe

mundipharma pty ltd - leuprorelin acetate, quantity: 7.5 mg - injection, modified release - excipient ingredients: n-methyl-2-pyrrolidone; polyglactin - eligard 7.5mg 1 month, eligard 22.5mg 3 month, eligard 30mg 4 month and eligard 45mg 6 month are indicated for the:,? palliative treatment of advanced prostate cancer.,? treatment of high-risk localised and locally advanced hormone-dependent prostate cancer in combination with radiotherapy.1

ELIGARD leuprorelin acetate 45 mg modified release injection syringe Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

eligard leuprorelin acetate 45 mg modified release injection syringe

mundipharma pty ltd - leuprorelin acetate, quantity: 45 mg - injection, modified release - excipient ingredients: polyglactin; n-methyl-2-pyrrolidone - prostate cancer,eligard 7.5mg 1 month, eligard 22.5mg 3 month, eligard 30mg 4 month and eligard 45mg 6 month are indicated for the:,? palliative treatment of advanced prostate cancer.,? treatment of high-risk localised and locally advanced hormone-dependent prostate cancer in combination with radiotherapy.,central precocious puberty (cpp),eligard 45mg 6 month is indicated for the treatment of children 2 years of age and older with central precocious puberty (cpp).

ELIGARD leuprorelin acetate 30mg modified release injection syringe Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

eligard leuprorelin acetate 30mg modified release injection syringe

mundipharma pty ltd - leuprorelin acetate, quantity: 30 mg - injection, modified release - excipient ingredients: n-methyl-2-pyrrolidone; polyglactin - prostate cancer,eligard 7.5mg 1 month, eligard 22.5mg 3 month, eligard 30mg 4 month and eligard 45mg 6 month are indicated for the:,? palliative treatment of advanced prostate cancer.,? treatment of high-risk localised and locally advanced hormone-dependent prostate cancer in combination with radiotherapy.

ELIGARD leuprorelin acetate 22.5mg modified release injection syringe Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

eligard leuprorelin acetate 22.5mg modified release injection syringe

mundipharma pty ltd - leuprorelin acetate, quantity: 22.5 mg - injection, modified release - excipient ingredients: n-methyl-2-pyrrolidone; polyglactin - prostate cancer,eligard 7.5mg 1 month, eligard 22.5mg 3 month, eligard 30mg 4 month and eligard 45mg 6 month are indicated for the:,? palliative treatment of advanced prostate cancer.,? treatment of high-risk localised and locally advanced hormone-dependent prostate cancer in combination with radiotherapy.

ELIGARD 22.5 MG Իսրայել - անգլերեն - Ministry of Health

eligard 22.5 mg

kamada ltd, israel - leuprorelin acetate - powder and solvent for solution for injection - leuprorelin acetate 22.5 mg - eligard is indicated for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localized and locally advanced hormone dependent prostate cancer in combination with radiotherapy.

ELIGARD 45 MG Իսրայել - անգլերեն - Ministry of Health

eligard 45 mg

kamada ltd, israel - leuprorelin acetate - powder and solvent for solution for injection - leuprorelin acetate 45 mg - eligard is indicated for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localized and locally advanced hormone dependent prostate cancer in combination with radiotherapy.

ELIGARD 7.5 MG Իսրայել - անգլերեն - Ministry of Health

eligard 7.5 mg

kamada ltd, israel - leuprorelin acetate - powder and solvent for solution for injection - leuprorelin acetate 7.5 mg - eligard is indicated for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localized and locally advanced hormone dependent prostate cancer in combination with radiotherapy.

ELIGARD ® POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 22.5mg Սինգապուր - անգլերեն - HSA (Health Sciences Authority)

eligard ® powder and solvent for solution for injection 22.5mg

dch auriga singapore - leuprorelin 20.87 mg eqv to leuprorelin acetate - injection, powder, lyophilized, for suspension,extended release - 22.5 mg - leuprorelin 20.87 mg eqv to leuprorelin acetate 22.5 mg

ELIGARD ® POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 45mg Սինգապուր - անգլերեն - HSA (Health Sciences Authority)

eligard ® powder and solvent for solution for injection 45mg

dch auriga singapore - leuprorelin 41.7 mg eqv leuprorelin acetate - injection, powder, lyophilized, for suspension,extended release - 45mg - leuprorelin 41.7 mg eqv leuprorelin acetate 45mg